Verona Pharma Plc ADR (NASDAQ: VRNA) kicked off on Friday, down -7.03% from the previous trading day, before settling in for the closing price of $22.61. Over the past 52 weeks, VRNA has traded in a range of $11.39-$23.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -39.77%. While this was happening, its average annual earnings per share was recorded -119.44%. With a float of $62.41 million, this company’s outstanding shares have now reached $80.44 million.
The extent of productivity of a business whose workforce counts for 79 workers is very important to gauge.
Verona Pharma Plc ADR (VRNA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 23.03%, while institutional ownership is 61.31%. The most recent insider transaction that took place on May 03 ’24, was worth 71,032. In this transaction Chief Medical Officer of this company sold 36,248 shares at a rate of $1.96, taking the stock ownership to the 2,621,552 shares. Before that another transaction happened on Feb 05 ’24, when Company’s Chief Medical Officer sold 36,248 for $2.22, making the entire transaction worth $80,503. This insider now owns 2,731,624 shares in total.
Verona Pharma Plc ADR (VRNA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -119.44% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Take a look at Verona Pharma Plc ADR’s (VRNA) current performance indicators. Last quarter, stock had a quick ratio of 18.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.18 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
The latest stats from [Verona Pharma Plc ADR, VRNA] show that its last 5-days average volume of 0.75 million was inferior to 0.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 52.39%. Additionally, its Average True Range was 1.29.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 78.10%, which indicates a significant increase from 18.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.87% in the past 14 days, which was lower than the 59.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.89, while its 200-day Moving Average is $16.18. Now, the first resistance to watch is $21.78. This is followed by the second major resistance level at $22.55. The third major resistance level sits at $23.23. If the price goes on to break the first support level at $20.33, it is likely to go to the next support level at $19.65. The third support level lies at $18.88 if the price breaches the second support level.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
The company with the Market Capitalisation of 1.70 billion has total of 79,480K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -54,370 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -25,790 K.
